Key Stats for Alumis Stock
- Price Change for Alumis stock: 95%
- $ALMS Share Price as of Jan. 6: $16.23
- 52-Week High: $22.30
- $ALMS Share Price Target: $24
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Alumis (ALMS) stock exploded nearly 100% on Tuesday after the company released breakthrough Phase 3 trial results for envudeucitinib, its next-generation psoriasis treatment.
The late-stage biopharmaceutical company announced that its oral TYK2 inhibitor met all primary and secondary endpoints in two separate Phase 3 trials, demonstrating superior skin clearance compared to placebo and existing treatments.
The results were impressive across the board. At Week 16, 74% of patients achieved PASI 75 (a 75% improvement in psoriasis symptoms) and 59% achieved nearly clear or completely clear skin.
By Week 24, approximately 65% of patients had achieved PASI 90 (90% improvement), and more than 40% had achieved complete skin clearance with PASI 100.
What makes these results particularly compelling is how quickly the drug worked. Alumis stock benefited from data showing clear separation from placebo as early as Week 4, suggesting patients could see meaningful improvements in just one month.
The drug also beat apremilast, a commonly prescribed oral psoriasis medication, on all skin clearance measures at Week 24.
See analysts’ growth forecasts and price targets for ALMS stock (It’s free!) >>>
What the Market Is Telling Us About ALMS Stock
The massive surge in Alumis stock signals that investors believe envudeucitinib could be a game-changer in the psoriasis market. Historically, patients seeking the highest levels of skin clearance had to use injectable biologics, as oral medications weren’t effective enough.
These Phase 3 results suggest that envudeucitinib might finally bridge that gap, offering biologic-like efficacy in a convenient pill form.
Dr. Andrew Blauvelt, a leading psoriasis expert, captured the significance: “For individuals seeking the best chance for clearance, biologics have long been superior to oral therapies. But now, with these new data on envudeucitinib, we’re seeing an exciting possibility of a new oral drug for psoriasis that can deliver high levels of efficacy in a safe manner.”
The safety profile also looks favorable. Most side effects were mild to moderate, including headaches, nasopharyngitis, upper respiratory infections, and acne. No new safety signals emerged, consistent with earlier trial data.
Alumis plans to submit a New Drug Application to the FDA in the second half of 2026. The company is also testing envudeucitinib for systemic lupus erythematosus, with Phase 2b results expected in Q3 2026, which could further expand the drug’s commercial opportunity.
For investors watching Alumis stock, the company appears positioned at the forefront of a new generation of psoriasis treatments that could reshape how patients manage this chronic condition.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Alumis Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
